New Jersey v. Exxon Corp. No. 1:99CV03183 (D.D.C. Nov. 30, 1999); Alaska v. Exxon Corp. No. A99-618-CV (D. Alaska, Nov. 30, 1999); Texas v. Exxon Corp. No. 3-99CV 2709-L (N.D. Texas, Dallas, Dec. 3, 1999); California v. Exxon

Plaintiff States sought to enjoin the merger between Exxon Corporation (Exxon) and Mobil Corporation (Mobil), alleging that the merger would violate Section 7 of the Clayton Act because the acquisition would substantially lessen competition and/or tend to lessen competition in relevant markets in each of the States.

Read More →

In re Compact Disc Minimum Advertised Price Antitrust Litigation MDL No. 1361 (D. Me. 2002) MDL-1391; No. 00-CIV-5853 (BSJ) (S.D.N.Y Aug. 8, 2000) (complaint)

Plaintiff States sought damages and injunctive relief, alleging that Defendant CD distributors unlawfully conspired to implement stringent minimum advertised price (MAP) policies in violation of antitrust laws.

Read More →

California v. BP Amoco/p.l.c., 3:00-cv-00420-SI (N.D. Cal, Apr. 13, 2000); In the Matter of the British Petroleum Company and Amoco Corp. File No. 981-0345 1998 WL 910216

Plaintiff States, jointly with the Federal Trade Commission, sought to enjoin the merger between British Petroleum Company (BP) and Amoco Corporation (Amoco). It was alleged that the proposed merger would effectively reduce competition or create a monopoly in the sale of gasoline.

Read More →

In re: Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.) (see also Ohio v. Bristol Myers Squibb

Plaintiff States sought damages and injunctive relief, alleging that Bristol-Myers Squibb Co. (BMS) attempted to maintain an unlawful monopoly on buspirone hydrochloride, a medication used to treat generalized anxiety. In settling, BMS agreed to a stipulated injunction and to reimburse consumers and state and local public entities for overcharges. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlement, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.

Read More →

In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)

Plaintiff States sought damages and injunctive relief, alleging that defendants entered into an unlawful agreement attempting to delay or prevent the marketing of less expensive generic alternatives to Cardizem CD, a brand name drug used to prevent heart attacks. The Plaintiff States settled for $80 million, the bulk of which was to be used to reimburse purchasers including consumers, insurance companies and other third-party payers for overcharges paid for Cardizem CD between 1998 and 2003.

Read More →

New York v. Nintendo of America, Inc., 775 F. Supp. 671 (S.D.N.Y. 1991)

Plaintiff States sought damages and injunctive relief, alleging that Nintendo Corporation, Ltd. (Nintendo) engaged in a conspiracy with dealers to fix or maintain the resale price for which the Nintendo Entertainment System video console could be sold.

Read More →

In Re: Toys ‘R’ Us Antitrust Litigation, 191 F.R.D. 347 (E.D.N.Y. 2000); M.D.L. 1211

Plaintiff States alleged that Toys R Us entered into vertical and horizontal agreements with numerous toy manufacturers to limit the supply of certain popular toys to warehouse clubs.

Read More →

Missouri v. American Cyanamid Co.; 1997 U.S. Dist. LEXIS 4722,.1997-1 Trade Cas. (CCH) 71,712 (W.D. MO. 1997)

The Plaintiff States alleged that between 1989 and 1995, American Cyanamid Company (American Cyanamid) entered into contracts for Crop Protection Chemicals (CPC), with its dealers in which they agreed formally and in writing to a rebate program that held floor prices at levels equal to Defendant’s wholesale prices for affected CPC.

Read More →

Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.)

Plaintiff States sought damages and injunctive relief, alleging that the drug company, Bristol-Myers Squibb, Co. (BMS) wrongfully maintained a monopoly on Taxol, a drug for which the Plaintiff States alleged Defendant fraudulently filed a patent. BMS’s alleged wrongful action delayed entry into the market by generic competitors of the drug, resulting in higher prices for Taxol. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlemen, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.

Read More →

New York et al. v. Reebok International, Ltd; 1995-1 Trade Cas. 71,558 (CCH), 96 F.3d 44, 903 F. Supp. 532 (S.D.N.Y. 1995)

Plaintiff States sought damages and injunctive relief, alleging that Reebok International Ltd. (Reebok) and The Rockport
Company (Rockport) conspired with certain dealers to set the minimum retail prices at which retailers were permitted to sell Reebok and Rockport women?s athletic footwear to consumers.

Read More →